#1 Clinical Trials Search in Europe

Methylprednisolone Hydrogen Succinate

This article explores clinical trials that compare different formulations of methylprednisolone, a commonly used corticosteroid medication. These studies aim to determine whether a new liquid form of the drug (oral suspension) is as effective as the traditional tablet form. The trials focus on how the body processes and absorbs these different formulations, which is crucial for ensuring that patients receive the same benefits regardless of the form they take.

Table of Contents

What is Methylprednisolone Hydrogen Succinate?

Methylprednisolone hydrogen succinate is a corticosteroid medication used to treat various inflammatory conditions in the body. It belongs to a class of drugs known as glucocorticoids, which are synthetic versions of hormones naturally produced by the adrenal glands[1]. This medication is also known by other names such as methylprednisolone, Solu-Mederin, or Urbason[2].

Medical Uses

Methylprednisolone hydrogen succinate is used to treat a wide range of medical conditions, including:

  • Acute Severe Asthma: It is used in emergency situations to quickly reduce inflammation in the airways and improve breathing[1].
  • Membranous Nephropathy: This is a kidney disorder where methylprednisolone may be used as part of a treatment regimen to reduce inflammation and protein loss through urine[2].
  • Other Inflammatory Conditions: It can be used to treat various autoimmune and inflammatory disorders throughout the body.

Available Formulations

Methylprednisolone hydrogen succinate is available in several forms to suit different medical needs and patient preferences:

  • Tablets: Oral tablets of various strengths (e.g., 16 mg, 32 mg) for convenient dosing[3].
  • Powder for Oral Suspension: A new formulation being developed, which is a powder that can be mixed with liquid to create a suspension. This may be easier for some patients to swallow[3].
  • Intravenous (IV) Injection: Used in hospital settings for rapid effect, especially in emergency situations like severe asthma attacks[2].

Bioequivalence Studies

Researchers are conducting studies to compare the effectiveness of different formulations of methylprednisolone:

  • Tablet vs. Suspension: Studies are comparing how well the body absorbs the medication from tablets versus the new suspension form. This is done under both fasting and fed conditions to see if food affects absorption[4][5].
  • Bioavailability Measurements: Scientists measure things like the maximum concentration of the drug in the blood (Cmax) and how long the drug stays in the body (AUC) to ensure different forms work equally well[6].

These studies help ensure that patients receive the same benefits regardless of which form of the medication they take.

Administration and Dosage

The way methylprednisolone is given depends on the condition being treated and the formulation used:

  • Oral Tablets: Usually taken with food to reduce stomach upset. The dose can vary widely depending on the condition.
  • Oral Suspension: The powder is mixed with water to create a liquid that can be swallowed. This may be helpful for people who have difficulty swallowing tablets[3].
  • IV Injection: In hospital settings, it may be given as a large dose (e.g., 1g) over several days for severe conditions[2].

Always follow your doctor’s instructions carefully when taking this medication.

Potential Side Effects

Like all medications, methylprednisolone can cause side effects. Some potential side effects include:

  • Increased appetite and weight gain
  • Mood changes or difficulty sleeping
  • Increased risk of infections
  • Changes in blood sugar levels
  • Fluid retention

Long-term use may lead to more serious side effects, which is why doctors carefully monitor patients on this medication. Always discuss any concerns or new symptoms with your healthcare provider[2].

Aspect Details
Drug Formulations Methylprednisolone powder for oral suspension (4 mg/mL) vs. Methylprednisolone tablets (16 mg and 32 mg)
Study Designs Phase 1, open-label, randomized, single-dose, crossover bioequivalence studies
Conditions Tested Fasted and fed states
Primary Outcomes AUC (Area Under the Curve), Cmax (Maximum Concentration)
Secondary Outcomes Tmax (Time to Maximum Concentration), AUClast, Half-life
Measurement Timeframes 0 to 24 hours post-dose, with multiple time points in between
Purpose To determine bioequivalence between liquid and tablet formulations of methylprednisolone

FAQ

  • What is the main purpose of these clinical trials? The main purpose of these trials is to compare the bioavailability and bioequivalence of a new liquid formulation of methylprednisolone (oral suspension) to the existing tablet form. This helps determine if the new formulation works as effectively as the tablets.
  • What does 'bioequivalence' mean in these studies? Bioequivalence means that two different formulations of a drug have the same effect in the body. In these trials, researchers are checking if the liquid and tablet forms of methylprednisolone produce similar levels of the drug in the bloodstream over time.
  • How are these trials conducted? The trials are typically phase 1, open-label, randomized, single-dose studies. Participants receive either the liquid or tablet form of methylprednisolone, and researchers measure drug levels in their blood at various time points after dosing.
  • What are the main outcomes measured in these trials? The main outcomes measured are the area under the concentration-time curve (AUC), which shows total drug exposure over time, and the maximum concentration (Cmax) of the drug in the blood. Secondary outcomes include the time to reach maximum concentration (Tmax).
  • Why is it important to study different formulations of methylprednisolone? Studying different formulations is important to provide options for patients who may have difficulty swallowing tablets or prefer liquid medication. It ensures that alternative forms of the medication are just as effective as the standard tablet form.

Ongoing Clinical Trials on Methylprednisolone Hydrogen Succinate

  • Study of immunosuppression reduction in kidney transplant patients with septic shock or respiratory failure receiving drug combination therapy in intensive care

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Safety of Eight Treg and Drug Combination for Patients with Chronic Kidney Failure Undergoing Transplant from a Living Donor

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Methylprednisolone and Prednisone for Treating Acute Flare-Ups in Idiopathic Pulmonary Fibrosis Patients

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Methylprednisolone in Infants with Neuroendocrine Cell Hyperplasia

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Rituximab for Patients with Amyotrophic Lateral Sclerosis (ALS)

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on High-Dose Methylprednisolone and Prednisolone for Children with Stroke Due to Focal Cerebral Arteriopathy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Denmark France Germany Sweden

  • Study on the Effects of Methylprednisolone and Placebo on Ventilator Support Duration in Severe COPD Patients in Intensive Care

    Not recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on the Effects of Methylprednisolone and Sodium Chloride in Patients Undergoing Surgery for Digestive Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Bioavailability: The extent and rate at which a drug enters the body's circulation and becomes available at the site of action.
  • Bioequivalence: When two medications have the same active ingredient and produce the same effect in the body, despite having different formulations.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, calculated from a graph of drug concentration in the blood versus time.
  • Cmax: The maximum concentration of a drug observed in the blood after a dose is given.
  • Tmax: The time it takes for a drug to reach its maximum concentration in the blood after a dose is given.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being given.
  • Randomized study: A study design where participants are randomly assigned to different treatment groups to reduce bias.
  • Crossover study: A study where participants receive different treatments at different times, allowing each person to serve as their own control.
  • Fasted conditions: When a study is conducted with participants who have not eaten for a specified period before taking the medication.
  • Fed conditions: When a study is conducted with participants who have eaten a meal before taking the medication.

References

  1. https://clinicaltrials.gov/study/NCT06171932
  2. https://clinicaltrials.gov/study/NCT01955187
  3. https://clinicaltrials.gov/study/NCT01267201
  4. https://clinicaltrials.gov/study/NCT01405131
  5. https://clinicaltrials.gov/study/NCT01405170
  6. https://clinicaltrials.gov/study/NCT01405157